Sutro Biopharma Inc (STRO)
3.50
+0.02
(+0.57%)
USD |
NASDAQ |
Sep 27, 16:00
3.50
0.00 (0.00%)
After-Hours: 20:00
Sutro Biopharma Research and Development Expense (TTM): 218.33M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 218.33M |
| March 31, 2024 | 197.90M |
| December 31, 2023 | 180.42M |
| September 30, 2023 | 169.80M |
| June 30, 2023 | 155.84M |
| March 31, 2023 | 146.58M |
| December 31, 2022 | 137.17M |
| September 30, 2022 | 123.96M |
| June 30, 2022 | 118.85M |
| March 31, 2022 | 111.83M |
| December 31, 2021 | 104.40M |
| September 30, 2021 | 97.21M |
| June 30, 2021 | 89.97M |
| Date | Value |
|---|---|
| March 31, 2021 | 81.90M |
| December 31, 2020 | 76.96M |
| September 30, 2020 | 71.62M |
| June 30, 2020 | 69.15M |
| March 31, 2020 | 68.05M |
| December 31, 2019 | 65.61M |
| September 30, 2019 | 63.01M |
| June 30, 2019 | 58.75M |
| March 31, 2019 | 56.36M |
| December 31, 2018 | 54.26M |
| September 30, 2018 | 54.62M |
| June 30, 2018 | 55.64M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
63.01M
Minimum
Sep 2019
218.33M
Maximum
Jun 2024
117.43M
Average
108.11M
Median
Research and Development Expense (TTM) Benchmarks
| Fulcrum Therapeutics Inc | 74.27M |
| NovaBay Pharmaceuticals Inc | 0.043M |
| Palatin Technologies Inc | 25.13M |
| iBio Inc | 5.185M |
| Theriva Biologics Inc | 14.61M |